Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial
To investigate the efficacy and safety of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen (FlexibleMIB) compared with placebo to treat endometriosis-associated pelvic pain (EAPP).
Source: fertstert.org
Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial
Published in Embryology and Reproductive Medicine
More from Embryology and Reproductive MedicineMore posts in Embryology and Reproductive Medicine »
- Life after Stillbirth
- The possible impact of COVID 19 on fertility and ART
- Human embryonic stem cell–derived blastocyst-like spheroids resemble human trophectoderm during early implantation process
- What support is available for you in hospital if you lose your baby
- Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis
Be First to Comment